Houston-based medical device company Procyrion, Inc. has been particularly active in biotech news in 2014, having announced a new scientific advisory board in January, followed by news that the company had been awarded $1.5 million in state funding from the Texas Emerging Technology Fund, and was recognized by the Rice Alliance as a “Top Life Science Company” for its Aortix™ medical device. As buzz about Procyrion and its novel Aortix device continues to gain momentum in the medical marketplace, the company has now announced that it will present its catheter-deployed circulatory assist device at the American College of Cardiology 63rd Annual Scientific Session and Expo (ACC.14) scheduled for March 29–31 in Washington D.C.
Intended for long-term use in the treatment of chronic heart failure, the Aortix™ device is the creation of Texas-based Dr. Reynolds M. Delgado III, who serves as Medical Director of Mechanical Support at the Texas Heart Institute. What sets the Aortix apart from other designs is the device’s percutaneous intra-aortic continuous flow pump, which is delivered by a catheter inserted through the femoral artery and held in place using novel self-expanding anchors, according to a company press release. Procyrion goes on to explain that Aortix is particularly advantageous to treating chronic heart failure over the long term due to its small size and unique design of the device, which makes for a remarkably minimally invasive outpatient procedure. Incredibly, the procedure only takes about ten minutes to complete.
Procyrion President and CEO Benjamin Hertzog explained that, “Our primary focus is to dramatically shift the risk profile of mechanical circulatory support and bring long-term circulatory support to the cath-lab. ACC.14 is a perfect opportunity to present Aortix™ to the world’s leading cardiovascular specialists.” It is anticipated that ACC.14 will draw 20,000 attendees from 109 countries this year, which will give the company a unique opportunity to further present the efficacy of the Aortix to the Cardiological community.
Procyrion also announced that it will present Aortix™ at the International Society for Heart and Lung Transplantation’s 34th Annual Meeting & Scientific Session in San Diego April 10–13, 2014.